Please login to the form below

Not currently logged in
Email:
Password:

Restasis

This page shows the latest Restasis news and features for those working in and with pharma, biotech and healthcare.

Shire rebuffs Takeda bids, as Allergan bows out

Shire rebuffs Takeda bids, as Allergan bows out

a bid to reduce costs as it faces tougher competition for dry eye treatment Restasis, its second-biggest product after Botox.

Latest news

More from news
Approximately 3 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    In second position, Allergan experienced modest sales growth of 2.3%. “Allergan’s main ophthalmology product - Restasis - is the go-to treatment for dry eye, but is due to go off

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Indians scalp cowboys in patent war

    It involves an unlikely alliance with a native American tribe.  . How?  . To defend its dry eye treatment Restasis (ciclosporin) against generic competition, Allergan has transferred the patent to the St Regis ... The Restasis case is not so much an

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics